Pilot Study of Sodium-Glucose Cotransporter 2 Inhibitor Empagliflozin Shows Reduced Intrarenal Complement Activation in Patients With Diabetes and CKD - Mia Jensen; Steffen F. Nielsen; Steffen Thiel; Søren W.K. Hansen; Yaseelan Palarasah; Per Svenningsen; Jesper N. Bech; Frank H. Mose; Boye L. Jensen (Kidney International Reports)